Literature DB >> 10215217

The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure.

E A Rose1, A J Moskowitz, M Packer, J A Sollano, D L Williams, A R Tierney, D F Heitjan, P Meier, D D Ascheim, R G Levitan, A D Weinberg, L W Stevenson, P A Shapiro, R M Lazar, J T Watson, D J Goldstein, A C Gelijns.   

Abstract

BACKGROUND: Because left ventricular assist devices have recently been approved by the Food and Drug Administration to support the circulation of patients with end-stage heart failure awaiting cardiac transplantation, these devices are increasingly being considered as a potential alternative to biologic cardiac replacement. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial is a multicenter study supported by the National Heart, Lung, and Blood Institute to compare long-term implantation of left ventricular assist devices with optimal medical management for patients with end-stage heart failure who require, but do not qualify to receive cardiac transplantation.
METHODS: We discuss the rationale for conducting REMATCH, the obstacles to designing this and other randomized surgical trials, the lessons learned in conducting the multicenter pilot study, and the features of the REMATCH study design (objectives, target population, treatments, end points, analysis, and trial organization).
CONCLUSIONS: We consider what will be learned from REMATCH, expectations for expanding the use of left ventricular assist devices, and future directions for assessing clinical procedures.

Entities:  

Mesh:

Year:  1999        PMID: 10215217     DOI: 10.1016/s0003-4975(99)00042-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  41 in total

Review 1.  Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy.

Authors:  P Elliott
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 2.  Rational use of inotropic therapy in heart failure.

Authors:  G M Felker; C M O'Connor
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

3.  Mechanical circulatory support: expanding knowledge and experience in a challenging patient subset.

Authors:  W L Holman
Journal:  Intensive Care Med       Date:  2001-08       Impact factor: 17.440

4.  Left Ventricular Assist Devices as Destination Therapy for End-stage Heart Failure.

Authors:  Lynne Warner Stevenson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-12

5.  An overview of approved and investigational left ventricular assist devices.

Authors:  Randy Marcel; Dan M Meyer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

6.  Thirty-five years of mechanical circulatory support at the Texas Heart Institute: an updated overview.

Authors:  Courtney J Gemmato; Matthew D Forrester; Timothy J Myers; O H Frazier; Denton A Cooley
Journal:  Tex Heart Inst J       Date:  2005

Review 7.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 8.  Total artificial hearts: past, present, and future.

Authors:  William E Cohn; Daniel L Timms; O H Frazier
Journal:  Nat Rev Cardiol       Date:  2015-06-02       Impact factor: 32.419

9.  Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support.

Authors:  J Raymond Fitzpatrick; John R Frederick; Vivian M Hsu; Elliott D Kozin; Mary Lou O'Hara; Elan Howell; Deborah Dougherty; Ryan C McCormick; Carine A Laporte; Jeffrey E Cohen; Kevin W Southerland; Jessica L Howard; Mariell L Jessup; Rohinton J Morris; Michael A Acker; Y Joseph Woo
Journal:  J Heart Lung Transplant       Date:  2008-12       Impact factor: 10.247

10.  Comparing administration of questionnaires via the internet to pen-and-paper in patients with heart failure: randomized controlled trial.

Authors:  Robert C Wu; Kevin Thorpe; Heather Ross; Vaska Micevski; Christine Marquez; Sharon E Straus
Journal:  J Med Internet Res       Date:  2009-02-06       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.